Clinical Trial Update: Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fed Conditions [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated bioequivalence of metoprolol succinate extended-release 200 mg under fed conditions and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Heart Failure
• Hypertension

Drugs mentioned

• Metoprolol succinate extended-release tablets (metoprolol succinate)

Snippet

Sponsor: IPCA Laboratories Ltd. | Conditions: Fed | Phase 1 | Status: COMPLETED